CrossAssetDataThe Company File
···
BTMD

Biote Corp.

Biote Corp. is classed by the SEC under Medicinal Chemicals & Botanical Products (industry code 2833), based in Irving, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $192 million and a profit of $27 million (its filed statements).

Product business Medicinal Chemicals & Botanical Products Irving, TX filings since 2020 9 of 9 filed
Ask the desk about BTMD → Compare BTMD with NAGE → Price chart on TradingView ↗ Full EDGAR file ↗ Watch BTMD →

Sector peers: NAGEFTLFNAIIMDWD

4.7/10headline grade
vs its business-model standard
4.4/10past 4.2/10present 5.6/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2833, Medicinal Chemicals & Botanical Products); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 4.7 out of ten, 9 of 9 metrics filed: past 4.4 out of ten, present 4.2 out of ten, future 5.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 2.8 out of ten. 10 warning events since 2020; the latest 2023-03-24. 28th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 6.0 out of ten. +8.4% a year over 5 filed years; profitable in 4 of 5. 60th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 3.5 out of ten. Share count grew 65.7% a year. 22% of cash flow returned. Insiders: 0 sales, 2 purchases. 35th percentile among 9 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 3.0 out of ten. Leverage 154%: owes 154¢ per asset dollar. 30th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.5 out of ten. top 25% of 18 in its family; net margin 14.1%. 75th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 1.9 out of ten. bottom 19% of 12 in its family for leadership; chief executive since 2026. 19th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 5.0 out of ten. bottom 50% of 18 in its family for room to expand. 50th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 6.6 out of ten. top 34% of 18 in its family for growth drivers. 66th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 5.6 out of ten. top 44% of 18 in its family for expectations against reality. 56th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-03-13 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-07 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-09-18. Filings on record since 2020. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Pellet Procedures Product Revenue 71%, Dietary Supplements 22%, Disposable Trocars Product Revenue 3%, Other Service Revenue 2%, Shipping Fees and Other Product Revenue 1%, Contract Term Services Revenue 1%. As tagged in its annual report (Form 10-K, filed 2026-03-13).

Who runs it

Peterson, Robert Charles (Interim CEO); Christensen, Bret (Chief Executive Officer); Beer, Marc D (Executive Chairman); Heyer, Andrew R (President); Monico, Daniel Michael (General Counsel); Barrera, Richard R (director); Cone, Stephen Mark (director); Jacoby, Dana Lynn (director); Morris, Debra L (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.